Gilead, Merck agreement to develop HIV treatments lenacapavir and islatravir

By PBR Staff Writer

California-based biopharmaceutical company Gilead Sciences, Inc. and New Jersey-based Merck have announced their agreement to develop and commercialise the long-acting HIV treatments lenacapavir and islatravir.